Journal
DIABETES RESEARCH AND CLINICAL PRACTICE
Volume 91, Issue 2, Pages E30-E32Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2010.10.004
Keywords
Dipeptidil-peptidase 4 enzyme; Sitagliptin; Type 2 diabetes; Immunological effects
Categories
Ask authors/readers for more resources
We report the case of a type 2 diabetes subject who developed severe leucopenia associated with treatment with the dipeptidil-peptidase 4 enzyme inhibitor Sitagliptin and highlights DPP4 inhibitors as a possible cause of unexplained hematolgical abnormalities in patients receiving DPP4-inhibitor treatment. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
